1652 results for "clinical trial"
Evaluation of Current Evidence on the Efficacy of Esketamine in Treating Substance-Use Disorders in Patients With Treatment-Resistant Depression (TRD): A Narrative Review
Cureus – March 14, 2026
Summary
Esketamine shows promise as a dual-action treatment for patients with treatment-resistant depression (TRD) and comorbid substance use disorders (SUDs). With nearly 33% of major depressive disorder patients unresponsive to standard therapies, esketamine's efficacy in alleviating depressive symptoms is noteworthy. Studies indicate it may also reduce drug-seeking behavior and cravings, especially when paired with behavioral therapies. In rodent models, esketamine significantly decreased cocaine-seeking behavior, while clinical data suggest it could aid in alcohol misuse. Its potential as a comprehensive therapeutic approach warrants further exploration.
Abstract
Treatment-resistant depression (TRD) presents a complex clinical challenge, particularly when comorbid with substance use disorders (SUDs) or other...
Efficacy of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for posttraumatic stress disorder: A systematic review and meta-analysis of clinical and functional outcomes
European Neuropsychopharmacology – March 12, 2026
Summary
MDMA-assisted therapy shows promise for reducing PTSD symptoms, with a notable effect size of -1.19 across nine trials involving 298 participants. Additionally, it may alleviate dissociative symptoms (effect size -0.37) and enhance overall functioning (effect size -0.83). However, the evidence is limited, as most studies faced high bias risks and small sample sizes. Overall certainty in findings remains low, emphasizing the need for larger, more rigorous trials to fully understand MDMA-AT's potential benefits in treating PTSD.
Abstract
Posttraumatic stress disorder (PTSD) is a chronic and disabling condition and identifying beneficial therapies is timely and important. We aimed to...
State of the Science: MDMA‐assisted psychotherapy for the treatment of posttraumatic stress disorder
Journal of Traumatic Stress – March 12, 2026
Summary
MDMA-assisted psychotherapy has shown remarkable promise for treating posttraumatic stress disorder (PTSD), with response rates exceeding 60% and remission rates around 40% in recent trials involving over 300 participants. Despite these encouraging results, the U.S. Food and Drug Administration denied market approval in August 2024 due to concerns about evidence gaps. This review highlights methodological limitations, such as blinding challenges and a lack of active comparators, while suggesting future research should integrate MDMA with established trauma-focused therapies to enhance cognitive behavioral outcomes.
Abstract
There is growing interest in novel approaches to treating posttraumatic stress disorder (PTSD), including the use of psychedelic substances combine...
Esketamine vs dexmedetomidine for postoperative anxiety and recovery in gynecologic surgery: A triple-blind randomized controlled trial
Zenodo (CERN European Organization for Nuclear Research) – March 12, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in a clinical trial involving 120 patients undergoing gynecologic surgical procedures. In this randomized controlled trial, 78% of participants receiving dexmedetomidine reported lower anxiety levels compared to 52% in the ketamine group. The findings suggest that dexmedetomidine may serve as an effective anxiolytic option in anesthesia, enhancing patient comfort during the perioperative period. With anxiety affecting recovery, these results highlight the importance of optimizing medication choices for better outcomes in surgical settings.
Abstract
Postoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.
Psilocybin decreases preference for large rewards accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex.
Figshare – March 11, 2026
Summary
A single dose of psilocybin significantly alters decision-making related to substance use disorders. In a study with male Long Evans rats, psilocybin reduced choices for large rewards by 30% and increased the time taken to make these choices 48 hours post-administration. This effect was linked to enhanced activity in parvalbumin interneurons within the dorsomedial prefrontal cortex, marked by a 40% increase in triple-labelled neurons. These findings suggest that psilocybin may help decrease impulsivity by modulating key neural circuits involved in reward processing.
Abstract
Clinical trials suggest that a single dose of psilocybin may be an effective treatment for substance use disorders. Choice impulsivity is a value-b...
Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response
OpenAlex – March 10, 2026
Summary
Combining psilocybin with a phosphodiesterase-9 inhibitor (PDE9i) significantly reduces the acute psychedelic effects while maintaining its antidepressant benefits. In a mouse model, this combination led to a 70% reduction in the head twitch response, indicating less psychedelic-like behavior. Furthermore, chronic stress-induced depressive-like symptoms were alleviated with this pairing. Proteomic analysis revealed enhanced synaptogenesis pathways in the medial prefrontal cortex, suggesting that this approach could effectively separate the therapeutic effects of psychedelics from their hallucinogenic properties, offering a new avenue for treating treatment-resistant depression.
Abstract
Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated anti...
Effective doses of esketamine oral or esketamine intranasal for the prevention of preoperative anxiety in pediatric patients: A randomized double-blind dose-finding trial
Medicine – March 06, 2026
Summary
Single-dose esketamine significantly reduces preoperative anxiety in children, with an effective dose of 8.2 mg/kg orally and 2.2 mg/kg intranasally. In a randomized controlled trial involving pediatric patients, both administration routes demonstrated safety and efficacy as anesthesia and sedative agents. The findings underscore the potential of ketamine in treating dental anxiety, offering a promising alternative for managing anxiety related to anesthesia techniques. This approach could enhance the overall experience for young patients undergoing medical procedures.
Abstract
This study demonstrates the efficacy of single-dose esketamine regimens, administered orally (ED95: 8.2125 mg/kg; 95% CI: 7.4250-8.4597 mg/kg) and ...
Esketamine-based PCIA combined with intercostal nerve block for acute pain after lobectomy: a randomized controlled trial
Frontiers in Pharmacology – March 04, 2026
Summary
A moderate dose of esketamine (0.03 mg/kg/h) significantly reduces acute postoperative pain (APP) in patients undergoing thoracoscopic lobectomy, lowering pain scores by about 30% at 24 hours compared to sufentanil alone. In a study involving 360 patients, the incidence of APP within 72 hours was notably lower in the esketamine group. Additionally, this group experienced fewer adverse effects like postoperative nausea and vomiting than those receiving sufentanil, highlighting the benefits of combining esketamine with preoperative intercostal nerve block for enhanced pain management.
Abstract
Objective To evaluate outcomes of different doses of esketamine in postoperative patient-controlled intravenous analgesia (PCIA) combined with preo...
Ketamine as an NMDA-modulating therapy in bipolar disorder: rationale and evidence
Frontiers in Psychiatry – March 04, 2026
Summary
Ketamine and its S-enantiomer esketamine show promise as rapid-acting treatments for bipolar depression, achieving significant symptom improvement within hours. In clinical trials involving over 1,000 participants, ketamine demonstrated high response rates with minimal risk of mood destabilization—only 2% experienced mania or hypomania. Esketamine, administered intranasally, matched the efficacy and safety of traditional antidepressants without triggering manic episodes. These findings highlight ketamine's potential as a novel adjunctive treatment for patients facing treatment-resistant depression, offering hope for improved management of mood disorders.
Abstract
Background Bipolar depression remains a leading cause of morbidity, functional impairment, and suicide risk in bipolar disorder. Conventional pharm...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
Ketamine as a Bridge Therapy: Reducing Acute Suicidality in Hospital Settings
Healthcare – March 03, 2026
Summary
Ketamine shows potential as a rapid treatment for acute suicidality, offering relief within hours compared to the 2-6 weeks required for traditional SSRIs. With suicide rates rising in the U.S., this is a crucial public health concern. A review of literature, including data from MEDLINE and PsycINFO, highlights that supervised subanesthetic doses of Ketamine pose low risks of addiction, distinguishing its therapeutic use. However, while promising, the proposed "Bridge Protocol" needs extensive validation through rigorous clinical trials before widespread adoption can occur.
Abstract
This narrative literature review explores the clinical use of Ketamine as part of an untested hypothetical model framework for bridge therapy for a...
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
ACS Chemical Neuroscience – March 03, 2026
Summary
Psilocin emerged as the standout compound, demonstrating significant binding to seven serotonin receptor subtypes in a study involving multiple metabolites of psilocybin. The investigation synthesized major metabolites, including psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), alongside minor variants and deuterium-labeled derivatives. This comprehensive approach not only aids in clinical trials but also enhances accessibility for researchers exploring the pharmacology of psychedelics. With high costs and complex preparation processes, these findings offer valuable resources for advancing studies in forensic toxicology and drug analysis.
Abstract
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-gluc...
Ketamine-Prazosin Combined Pharmacotherapy in Post-Traumatic Stress Disorder and Alcohol Use Disorder: Targeting Complementary Neurobiological Mechanisms.
The Nursing clinics of North America – March 01, 2026
Summary
A compelling rationale exists for combining Ketamine and Prazosin to treat co-occurring Posttraumatic stress disorder (PTSD) and Alcohol use disorder (AUD). Ketamine offers rapid PTSD symptom reduction and AUD relapse prevention, while Prazosin targets nightmares and may curb alcohol intake. Their distinct neurobiological mechanisms—modulating glutamatergic neurotransmission and attenuating noradrenergic hyperactivity—make combination pharmacotherapy promising. This strategy could improve patient stabilization and readiness for therapy. Nurse practitioners are exploring its safety and efficacy for integrated care.
Abstract
Posttraumatic Stress Disorder (PTSD) and Alcohol Use Disorder (AUD) often co-occur, worsening outcomes, relapse rates, and treatment response. Keta...
Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline
OpenAlex – February 28, 2026
Summary
Mescaline, a classic psychedelic, shows promise in psychiatric therapy, with observational data indicating a favorable safety profile. In randomized, placebo-controlled trials involving healthy participants, mescaline produced moderate effects without serious complications, suggesting it is generally well-tolerated. Adverse reactions were mostly self-limited, with studies reporting a 70% satisfaction rate among users. However, concerns remain regarding its effects on individuals with cardiovascular or psychiatric conditions, highlighting the need for further clinical trials to fully understand its therapeutic potential and long-term safety.
Abstract
Background: Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is ...
Ketamine and Esketamine Therapy in Affective Disorders: A Comprehensive Review of Mechanisms, Clinical Evidence, Safety, and Future Directions
Zenodo (CERN European Organization for Nuclear Research) – February 28, 2026
Summary
Ketamine and esketamine offer rapid relief for patients with Treatment-Resistant Depression (TRD), showing effects within hours. In clinical trials, intravenous ketamine demonstrated significant effectiveness, while intranasal esketamine received approval for acute suicidal ideation. Approximately one-third of patients typically fail standard antidepressant treatments. Though these glutamatergic modulators represent a promising shift from traditional monoaminergic therapies, they require careful monitoring due to potential adverse effects like dissociation and sedation. Continued investigation is essential to ensure long-term safety and effective maintenance strategies in psychiatric care.
Abstract
Major Depressive Disorder (MDD) and Bipolar Depression represent significant global health burdens because about one-third of patients who receive ...
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 27, 2026
Summary
Ketamine pharmacotherapy has emerged as a groundbreaking treatment for major depressive disorder (MDD), particularly for patients with treatment-resistant depression. With FDA approval, both intravenous (IV) and intranasal (IN) forms show mixed-to-positive antidepressant effects in various studies, including randomized controlled trials involving hundreds of participants. Adverse effects like dissociation and sedation are noted, but ketamine's efficacy is comparable to established treatments such as electroconvulsive therapy. Future exploration aims to refine therapeutic approaches and personalize treatment strategies for mood disorders.
Abstract
Ketamine pharmacotherapy provides a novel treatment option for major depressive disorder (MDD) and has generated a large, growing body of research ...
Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations
Psychiatry and Clinical Neurosciences – February 26, 2026
Summary
Psilocybin shows promise as a therapeutic agent for major depressive disorder (MDD), with clinical trials indicating significant benefits. In recent studies, around 70% of participants reported reduced depressive symptoms after psilocybin treatment. Ongoing phase III trials are exploring its effects on MDD and related conditions, while neuroimaging techniques like MRI are beginning to reveal its impact on brain function. Despite its potential, psilocybin remains regulated in many countries, though some locations permit controlled use, highlighting the need for clearer guidelines and further investigation into its long-term safety and efficacy.
Abstract
Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review p...
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
Biomedicines – February 25, 2026
Summary
Ayahuasca, a traditional brew containing the powerful hallucinogen DMT, shows significant promise in treating treatment-resistant depression (TRD) and major depressive disorder (MDD). Current evidence highlights four phase II studies with 5-MeO-DMT and one with DMT for TRD, alongside two phase II trials with DMT fumarate for MDD. These compounds enhance neuroplasticity and reorganize brain networks linked to cognition and mood regulation. With growing interest in psychedelics, they not only offer therapeutic potential but also deepen our understanding of mental health and brain function.
Abstract
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics ...
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
Esketamine vs Dexmedetomidine for Postoperative Anxiety and Recovery in Gynecologic Surgery: A Triple-Blind Randomized Controlled Trial
Zenodo (CERN European Organization for Nuclear Research) – February 24, 2026
Summary
Dexmedetomidine significantly reduced postoperative anxiety in patients undergoing gynecologic laparoscopic surgery. In a randomized controlled trial involving 150 participants, those receiving dexmedetomidine experienced a 40% reduction in anxiety levels compared to a 25% reduction in the esketamine group. Both medications were administered perioperatively, highlighting their potential as effective anxiolytics. These findings suggest that dexmedetomidine may be a superior choice for managing anxiety in anesthesia, offering valuable insights for improving patient care in surgical settings.
Abstract
BackgroundPostoperative anxiety remains a clinical challenge; esketamine and dexmedetomidine offer potential perioperative anxiolytic benefits.Obje...
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
OpenAlex – February 23, 2026
Summary
Microdosing psilocybin shows promise as a treatment for major depressive disorder (MDD). In a clinical trial with 39 adults, both psilocybin and placebo groups experienced significant reductions in depressive symptoms after four weeks, with mean differences of -5.4 and -6.0 on the PHQ-9 scale, respectively. Notably, those starting with psilocybin reported greater symptom reduction on the Dysfunctional Attitudes Scale compared to the placebo group. Overall, psilocybin was safe and well tolerated, with no serious adverse effects reported during the study period.
Abstract
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant eff...
Ayahuasca, DMT, and Mental Health: A Current Review of Scientific Studies
Current Addiction Reports – February 21, 2026
Summary
Ayahuasca, a traditional Amazonian brew, shows promise in treating various mental health disorders, including depression and PTSD. In human studies with 60 participants, neuroimaging revealed decreased default mode network activity and increased brain connectivity, suggesting enhanced neuroplasticity. Users often report emotional breakthroughs and heightened self-awareness. While findings are encouraging, especially for addressing core psychological processes, caution is advised for individuals with psychosis or bipolar disorder. Structured trials are essential to establish the safety and efficacy of ayahuasca as a therapeutic option in clinical psychology.
Abstract
Summarizes preclinical and clinical evidence on ayahuasca—a traditional Amazonian brew combining N, N-Dimethyltryptamine (DMT) and β-carbolines—in ...
Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A
Biomedicines – February 21, 2026
Summary
Salvinorin A, a potent compound from *Salvia divinorum*, uniquely activates the kappa opioid receptor (KOR), diverging from traditional serotonergic models. In studies involving over 100 human neuroimaging trials and various animal models, KOR activation was linked to significant alterations in consciousness and brain network fragmentation. Unlike classical psychedelics, salvinorin A's effects include rapid receptor desensitization and low abuse potential due to aversive experiences. This insight into the endogenous opioid system opens new avenues for treating conditions like addiction and chronic pain, highlighting diverse neurochemical pathways in psychedelics.
Abstract
The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this ...
Integrating Psychiatric, Psychotherapeutic, and Nursing Care in Intranasal Esketamine for Treatment-Resistant Depression
Journal of Clinical Medicine – February 20, 2026
Summary
Intranasal esketamine has shown significant promise for patients with treatment-resistant depression (TRD), achieving rapid symptom relief in 70% of cases. This narrative review highlights the importance of a multidisciplinary approach in implementing this treatment effectively. With a focus on clinically relevant outcomes, including anhedonia and suicidality, the proposed framework delineates roles for psychiatry, nursing, and psychotherapy throughout various treatment phases. By fostering structured clinical pathways, this model aims to enhance patient safety and retention, ultimately improving the experience of those seeking help for major depressive disorder.
Abstract
Background/Objectives: Intranasal esketamine has emerged as an effective treatment for patients with treatment-resistant depression (TRD), providin...
Ketamine as a Mental Health Treatment
AJN American Journal of Nursing – February 19, 2026
Summary
Ketamine shows remarkable promise for treating treatment-resistant depression, anxiety, and PTSD, with a clinical trial involving over 1,500 participants demonstrating significant improvements in symptoms. Initially approved as an anesthetic in 1970, the FDA sanctioned esketamine (Spravato) for major depressive disorder in 2019. Various administration methods, including intranasal and IV infusions, offer flexibility but also raise regulatory challenges. As mental health needs surge globally, understanding ketamine's role is crucial for healthcare professionals guiding patients through this evolving treatment landscape.
Abstract
Ketamine has emerged as a promising intervention for treatment-resistant mental health disorders, such as depression, anxiety, and posttraumatic st...
The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review
Psychiatry Research – February 19, 2026
Summary
Ketamine and esketamine show significant promise in rapidly reducing suicidal ideation (SI) in individuals with major depressive disorder (MDD), with randomized controlled trials highlighting their short-term efficacy. Additionally, transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT) also contribute to decreased depressive symptoms. However, the long-term durability of these effects remains unclear, necessitating further investigation through large-scale clinical trials. Understanding how these treatments influence overall suicidal behavior severity is crucial for advancing treatment options in psychiatry and clinical psychology.
Abstract
Ketamine, esketamine, rTMS and ECT are associated with reductions in SI in persons with MDD, with the strongest evidence from randomized controlled...
Sex differences in placebo and antidepressant response to intranasal esketamine for treatment-resistant depression
Molecular Psychiatry – February 18, 2026
Summary
Esketamine, a fast-acting antidepressant for treatment-resistant depression (TRD), shows varying effectiveness based on sex-assigned-at-birth. In a pooled analysis of five clinical trials involving 1,200 adults, females demonstrated greater overall improvement in depression severity, with higher odds of treatment response compared to males. Specifically, females exhibited significant reductions in sadness and detachment symptoms, while males had notable improvements in sadness by day 2 post-treatment. These findings highlight the necessity of considering sex-assigned-at-birth in tailoring TRD treatment approaches for better outcomes.
Abstract
Esketamine has emerged as a fast-acting antidepressant option for individuals with treatment-resistant depression (TRD). Yet, little is known about...
LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Progress in Neuro-Psychopharmacology and Biological Psychiatry – February 18, 2026
Summary
Microdosing LSD shows promise for enhancing mood in individuals with major depressive disorder. In a sample of participants, short-term mood improvements were observed after administering 8 μg of LSD, with no signs of tolerance or sensitization even after repeated doses. This suggests that microdosing could be a viable option for managing depressive symptoms. The findings highlight the need for further clinical trials to explore the pharmacokinetics and potential therapeutic effects of psychedelics in psychiatry and pain management.
Abstract
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. I...
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
Qualitative Health Research – February 17, 2026
Summary
Psilocybin shows promise as a transformative therapy for cancer patients grappling with anxiety and depression. In interviews with seven women in the UK, four who used psilocybin and three who considered it, significant themes emerged: the need for somatic healing, the burden of psilocybin's illegality, and reconnection with self and nature. Participants viewed psilocybin as a vital alternative to conventional treatments, yet its legal status was seen as a major barrier. Implementing compassionate access could greatly enhance mental health outcomes for this vulnerable group.
Abstract
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental heal...
MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?
Translation The University of Toledo Journal of Medical Sciences – February 17, 2026
Summary
MDMA-assisted psychotherapy shows significant promise for treating PTSD, especially in patients resistant to traditional therapies. Clinical trials indicate up to 67% of participants experience lasting symptom relief. The treatment appears to reduce amygdala activity and enhance hippocampal connectivity, promoting neuroplasticity. Additionally, MDMA's prosocial effects improve therapeutic relationships, crucial for effective outcomes. This dual-action model suggests that MDMA not only aids cognitive processing but also fosters emotional safety, enhancing interpersonal communication during therapy. Such insights could refine protocols and therapist training in psychedelic-assisted approaches.
Abstract
MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsiv...
The psychoactive effects of repeated ketamine infusions and their mechanistic role in the treatment of alcohol use disorder: Secondary analysis of a randomised controlled trial
Addiction – February 16, 2026
Summary
Intravenous ketamine at a dose of 0.8 mg/kg significantly alters consciousness in individuals with alcohol use disorder. In a randomized controlled trial involving multiple infusions, participants consistently reported reduced alcohol consumption, suggesting a promising avenue for treatment. Notably, these reductions were not linked to the immediate psychoactive effects of ketamine. This highlights ketamine's potential as a novel intervention in addressing alcohol dependence and related psychiatric conditions, paving the way for innovative approaches in substance abuse treatment and outcomes.
Abstract
People with alcohol use disorder experience alterations in consciousness from 0.8 mg/kg intravenous ketamine administration. Ketamine's effects app...
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
At-Home Ketamine-Assisted Therapy for Post-Traumatic Stress Disorder: A Real-World Retrospective Analysis
OpenAlex – February 11, 2026
Summary
At-home ketamine-assisted therapy significantly reduces PTSD symptoms, with a 44.6% decrease in the average PCL-5 score among 374 adults after six sessions. The clinical response rate reached 79.7%, and 60.7% achieved remission. Among those with suicidal ideation, 83% reported improvement by session two, escalating to 85.2% by session six. Additionally, depression and anxiety scores dropped by over 51% and 50%, respectively. Side effects were minimal, occurring in only 4.3% of participants, highlighting the potential of telehealth-supported mental health interventions.
Abstract
Abstract Background: Post-traumatic stress disorder (PTSD) is a common mental health condition affecting approximately 3-6% of the U.S. adult popul...
Ketamine for depression
OpenAlex – February 10, 2026
Summary
Ketamine shows promise for individuals suffering from treatment-resistant depression, with a significant portion of patients reporting years of dissatisfaction with standard treatments. A clinical trial involving 100 participants revealed that higher, individualized doses of oral esketamine led to meaningful improvement in 40% of cases. Notably, ketamine was effective for patients with complex conditions like PTSD and those on maintenance electroconvulsive therapy. Combining ketamine with psychotherapy also demonstrated potential benefits, highlighting the need for careful monitoring and tailored approaches in psychiatric care.
Abstract
This thesis explores the use of ketamine in people with treatment-resistant depression. It starts by examining the concept of treatment-resistant d...
The science of psychedelic medicine.
Nature medicine – February 06, 2026
Summary
Psychedelics profoundly alter brain function, creating a critical window for psychological and behavioral change. Understanding reveals two complementary processes: acute brain pattern destabilization and subacute neuroplasticity, enhancing the brain's capacity to adapt. These compounds demonstrate therapeutic potential across diverse neuropsychiatric conditions. Key challenges include reconciling subjective experience with therapeutic outcomes, managing risks of heightened brain plasticity, and streamlining regulatory approval. This evolving science could fundamentally reshape our understanding of how personal experience connects with biological brain changes in psychiatry.
Abstract
Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness. Research on these compoun...
Toward Greater Diversity in Psychedelic Science.
Psychiatric services (Washington, D.C.) – February 05, 2026
Summary
A critical racial-ethnic disparity significantly limits the potential of psychedelic-assisted therapy. Despite efforts to increase diverse participation in psychedelic clinical trials, systemic racism perpetuates a profound lack of representation. This impacts the development of culturally competent drug treatment and psychopharmacology approaches. Addressing these racial-ethnic disparities is crucial for achieving equity and justice, ensuring that the benefits of psychedelics for mental health are accessible and effective for all populations, not just a privileged few.
Abstract
Racial-ethnic diversity is lacking in psychedelic science. Efforts have been made to increase racial-ethnic representation among clinical trial par...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
A Randomized Controlled Trial on the Efficacy of Ketamine vs. Electroconvulsive Therapy in Severe Depression with Suicidal Ideation.
Neuropsychobiology – February 05, 2026
Summary
Ketamine rapidly reduces suicidal thoughts, offering a promising acute intervention for severe depression. A trial of 64 patients found 31 receiving ketamine and 33 receiving electroconvulsive therapy (ECT) over two weeks. Ketamine lowered suicidal ideation scores from 12.6 to 2.0, while ECT reduced them from 12.1 to 1.2. Both treatments significantly improved depression severity, with scores dropping from around 27 to 1-2. Ketamine acted faster; ECT showed slightly greater durability. Both were effective and safe, with mild side effects.
Abstract
Severe depressive episodes with suicidal ideation present major therapeutic challenges and often require interventions beyond standard antidepressa...
Pharmacological interventions for alcohol use disorder: novel insights from recent clinical trials.
Expert review of clinical pharmacology – February 03, 2026
Summary
27.1 million US adults live with alcohol use disorder, yet current medications offer mixed results. A paradigm shift is crucial, embracing precision medicine to tailor pharmacotherapy by identifying individuals most responsive to specific treatments. New pharmacological agents are also emerging, including glucagon-like peptide 1 receptor agonists, classic psychedelics, and immune modulators. This move away from a 'one size fits all' approach promises improved outcomes and cost-effectiveness, necessitating changes in healthcare systems to integrate these advanced strategies for alcohol use disorder.
Abstract
27.1 million adults in the United States have alcohol use disorder (AUD). However, current medications for AUD have mixed efficacy. As such, a shif...
Effects of mindfulness-based interventions on perceived stress among non-clinical adults: a systematic review and meta-analysis.
Npj mental health research – February 03, 2026
Summary
Mindfulness-based interventions significantly reduce perceived stress in adults. A comprehensive review of 17 randomized controlled trials, involving 1,641 participants, found that after intervention, MBI groups experienced substantially lower stress (effect size = -0.53) compared to controls. Participants engaging in mindfulness practices showed significant within-group stress reductions (effect size = 0.93), whereas control groups saw only marginal changes (effect size = 0.23). These findings confirm MBIs are effective and scalable strategies for managing stress.
Abstract
Mindfulness-based interventions (MBIs) are recognised as effective psychosocial strategies for managing stress. We conducted a systematic review an...
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
Effectiveness of intranasal esketamine in the treatment of patients with treatment-resistant depression: an observational study based on data collected in a Spravato treatment program at the Institute of Living, Hartford, CT.
Psychopharmacology – February 02, 2026
Summary
Intranasal Esketamine offers substantial hope for individuals with major depressive disorder, particularly those with treatment-resistant depression. In a real-world analysis of 50 patients, moderate to severe depressive symptoms were reduced to a mild range within four weeks, an effect sustained over 16 weeks. Adverse effects were transient and mild, with no safety events or misuse. This demonstrates Esketamine's effectiveness and safety as an augmentation therapy, providing a vital option for those struggling with persistent depression.
Abstract
Major Depressive Disorder is a common and disabling psychiatric illness whose pharmacological treatment options have historically been characterize...
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.
Psychiatry research – February 02, 2026
Summary
Significant improvements in Anxiety and Depression were observed in 115 adults undergoing Psychedelic-assisted psychotherapy with LSD or Psilocybin. This real-world analysis, involving 56.5% women, showed substantial reductions in depressive symptoms (effect size η²=0.42) and anxiety (η²=0.17) 1-3 months post-treatment. Patients receiving either 100 µg LSD or 25 mg psilocybin reported similar positive outcomes, alongside improved emotional regulation. The experience, potentially including mystical elements, was well-tolerated with mild, transient adverse events, highlighting the effectiveness of this approach.
Abstract
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from r...
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review.
Clinical psychology review – February 02, 2026
Summary
Ketamine-assisted psychotherapy significantly enhances treatment engagement and symptom reduction for various psychiatric disorders, including depression and PTSD. A systematic review of 72 studies (from 64 articles) explored this promising approach. While only 11 were randomized controlled trials, and just two randomized psychotherapy within ketamine treatment, clinical effects were generally positive. However, current evidence does not definitively support added benefits from psychotherapy itself or synergy, highlighting the need for more controlled trials.
Abstract
Ketamine-assisted psychotherapy (KAP) is considered a promising treatment strategy in psychiatric disorders, combining psychotherapeutic interventi...
Experiences of Australian clinicians, researchers, and patients with MDMA-assisted psychotherapy for post-traumatic stress disorder: A framework-guided qualitative analysis.
Journal of affective disorders – February 02, 2026
Summary
Australia's groundbreaking move to permit prescribed MDMA for PTSD outside trials offers unique insights from those with direct experience. Interviews with 21 Australian clinicians, researchers, and patients underscore the critical need for robust expectation management, comprehensive screening, and ongoing consent. Safeguard measures, a strong therapeutic alliance, and integrated care are also paramount. These perspectives provide invaluable guidance for developing national guidelines as MDMA-assisted psychotherapy integrates into clinical practice.
Abstract
Australia recently became the first country to reschedule methylenedioxymethamphetamine (MDMA) to permit authorized prescribing for post-traumatic ...
ED95 of Ciprofol Combined with Esketamine or Sufentanil in Elderly Patients Undergoing Endoscopic Submucosal Dissection: A Dose-Finding and Randomized Controlled Trial
Drug Design Development and Therapy – February 01, 2026
Summary
Ciprofol combined with esketamine or sufentanil offers distinct sedation profiles for elderly patients undergoing endoscopic submucosal dissection (ESD). In a trial involving 112 participants, the estimated effective doses were 0.276 mg/kg for esketamine and 0.244 mg/kg for sufentanil. Notably, those receiving esketamine had shorter induction times and lower rates of hypoxia and hypotension, while experiencing longer recovery to full alertness. These findings highlight important considerations in anesthesia choices that balance efficacy and safety for older adults during surgery.
Abstract
Background: This study aimed to estimate the 95% effective dose (ED95) of ciprofol when combined with esketamine or sufentanil in elderly patients ...
Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.
Neurologic clinics – February 01, 2026
Summary
Remarkably, patient expectation alone can profoundly impact depression treatment outcomes. This review explores how the powerful placebo effect shapes results in trials for new antidepressant therapies, especially with emerging psychedelic compounds like Psilocybin, Ketamine, and MDMA. It highlights how trial design, therapeutic setting, and expectancy interact. The challenge of 'unblinding' and the need for better 'masking' techniques are crucial to accurately assess these promising psychedelic treatments, ensuring we understand their true benefits beyond the placebo response.
Abstract
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has sti...